Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Bonesupport Holding AB (publ)
Bonesupport makes injectable ceramic bone-graft substitutes that surgeons use to fill gaps and help broken or damaged bone heal.
Bonesupport is a Swedish medical device company that sells a very specific kind of product: a paste-like ceramic material that surgeons inject into a bone defect to help it heal. When bone is damaged by a fracture, an infection, or a surgery that leaves a gap, doctors often need something to fill that empty space. Bonesupport's product, sold under the brand name CERAMENT, does that job. It is a bio-ceramic bone graft substitute — a synthetic material that acts as a scaffold, slowly dissolving while new bone grows into it.
The company's customers are surgeons and hospitals, mainly orthopedic and trauma specialists, along with doctors treating bone infections. Bonesupport sells directly and through distributors in the United States, Europe, and other international markets, with the U.S. being its largest and most important market. What makes the product attractive is that it can be injected into the defect, which is less invasive than cutting, shaping, and packing traditional bone grafts. Its versions that carry antibiotics also let surgeons treat infection at the same time they rebuild the bone — a real advantage in a tricky clinical area. The business earns money by selling these single-use kits to hospitals for each procedure. It is a classic medtech model: build clinical evidence that the product works better or is easier to use than the alternatives, win over surgeons one at a time, and then ride repeat procedures as those surgeons keep using it. Competitors include other bone-graft and biomaterial makers, though Bonesupport's injectable, antibiotic-eluting niche gives it a distinctive position.
Bonesupport has been growing quickly. Revenue has climbed sharply in recent years as its U.S. business scaled up — for example, 2023 revenue rose by roughly a third to about €59 million, and growth stayed strong into 2024. That is the key thing to watch: whether it can keep expanding in the U.S., keep winning reimbursement, and turn that rapid growth into real profit. Medtech investors love a product that surgeons adopt and stick with, and Bonesupport's story is essentially about proving that its little injectable ceramic is one of those products.
Saved answer · last researched 12 Nov 2026